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Abstract 
Depression and dementia disorders have been suggested to share similar risk factors and 
pathogenetic background, such as cardiovascular risk factors, the apolipoprotein E (APOE) ɛ4 
allele, and white matter lesions. The renin-angiotensin system (RAS) may be involved in the 
pathogenesis of both dementia and depression due to its role in cardiovascular and metabolic 
homeostasis. In a previous study we reported an association between the well-known 
insertion/deletion polymorphism, rs1799752, in the gene encoding angiotensin-converting 
enzyme (ACE) and dementia at baseline in a population-based Swedish cohort of older 
individuals. In the present study, we extended our analyses of RAS-related gene variants to 
also include the SNP rs5186 in the angiotensin II type 1 receptor (AGTR1) gene and the 
phenotype late life depression. The purpose of the study was to examine the influence of the 
AGTR1 SNP, as well as the ACE I/D polymorphism, on both dementia and late-life depression 
in a population-based sample followed over twelve years. Like rs1799752 in ACE, rs5186 in 
AGTR1 was associated with dementia at baseline. None of the polymorphisms were 
associated with dementia during follow-up, but for rs1799752 this could be explained by a 
significant association with onset age. When the total number of individuals who developed 
major depression up to year 2009 was analyzed, significant associations, remaining after 
exclusion of dementia up to 2012, with rs1799752 in ACE were found. Overall, in the 
investigated population-based sample of older individuals, genetic variation in ACE, seems to 
be of importance for both dementia and major depression. Still, the results have to be 
interpreted with caution because of the small sample size, and further studies of the 
importance of these genes for dementia and late life depression in population based samples 
are warranted.  
  
 
 
Introduction 
Several studies suggest that depression and dementia disorders may share similar risk factors 
and pathogenetic background, including cardiovascular risk factors, the APOE-ɛ4 allele, and 
white matter lesions (Skoog et al. 1996; Skoog 2011; Gudmundsson et al. 2015; Skoog et al. 
2015). The renin-angiotensin system (RAS) may be involved in the pathogenesis of both 
dementia and depression due to its role in cardiovascular and metabolic homeostasis. Almost 
all organs, including the central nervous system, have their own local RAS with specific 
actions (Kehoe et al. 2009).  RAS is thought to be of importance in dementia disorders since it 
regulates blood pressure (including the cerebral blood flow), but also due to its effects on 
amyloid metabolism, memory and learning (Mogi et al. 2012). It may be important in 
depression due to its role in the hypothalamic-pituitary-adrenocortical (HPA) axis (Aguilera et 
al. 1995) and immune responses (Miller et al. 2009), which is of relevance also for dementia 
(Heppner et al. 2015; Martocchia et al. 2015). In addition, angiotensin II receptors (AGTR1) 
are found in regions crucial for mood regulation ((Tsutsumi and Saavedra 1991; Johren and 
Saavedra 1996).  
 
In RAS, angiotensinogen is converted to angiotensin I, which is converted to angiotensin II by 
the enzyme angiotensin converting enzyme (ACE). Angiotensin II exerts its effects through 
binding to different types of angiotensin II receptors, AGTR1 and AGTR2, where AGTR1 is 
the primary one (Skultetyova et al. 2007; Taylor et al. 2012). Genetic studies of the RAS-
system in relation to dementia have primarily focused on the ACE gene. The widely studied 
ACE insertion/deletion (I/D) polymorphism (rs1799752) is related to the activity level of the 
enzyme in the periphery (Rigat et al. 1990).  We have previously reported an association 
between this polymorphism and dementia in a population-based Swedish cohort (Gustafson et 
al. 2010). However, results from meta-analyses are inconsistent (Lehmann et al. 2005; Liu et 
al. 2009; Belbin et al. 2011). 
 
The recent International Genomics of Alzheimer’s Project provides suggestive evidence of 
associations between ACE single nucleotide polymorphisms (SNPs) and AD in a meta-
analysis of GWAS results (Lambert et al. 2013). In addition, another study using GWAS data 
in an attempt to replicate top findings from candidate gene studies in AD, reported variations 
in the ACE gene to be significantly associated with AD (Webster et al. 2010). Furthermore, 
the importance of the ACE gene in AD was confirmed in a recent study, primarily 
investigating associations between AD-related proteins and SNPs on a genome-wide basis, 
including a proxy-SNP (rs4343) in very high linkage disequilibrium with the I/D SNP 
rs1799752 (Kauwe et al. 2014). 
 
Another RAS-related gene is the angiotensin receptor II, type 1 (AGTR1) gene, which has 
been related to cardiovascular disorders, such as hypertension (Niu and Qi 2010) and 
myocardial infarction (Feng et al. 2014). To date, only one study has specifically investigated 
the relationship between AGTR1 and dementia, and this was a negative clinical study from 
South Korea on VaD (Kim et al. 2006).  
 
Previous studies of RAS-related genes in depression have also mainly focused on the ACE I/D 
variation rs1799752, but results are inconsistent (Lopez-Leon et al. 2008; Wu et al. 2012). 
Despite possible etiological differences between early and late onset depression (Blazer 2003; 
Otte et al. 2005; Kendler et al. 2009; Taylor et al. 2013), only one study have focused on the 
ACE gene in late-life depression. This study showed associations with several different ACE 
SNPs, e.g. the rs1799752 proxy rs4343 (Ancelin et al. 2013).  
 
Studies on the AGTR1-gene in depression are mainly based on clinical samples. One study 
report an association between the SNP rs5186 (A1166C), a variation of probable functional 
importance (Sethupathy et al. 2007), and major depression in a sample of mixed ages (Saab et 
al. 2007), while another found no association with late-life depression (Taylor et al. 2010). In 
addition, other variations in the AGTR1-gene were reported to be associated with late-life 
depression (Taylor et al. 2012). 
 
In the present study, we extended our analyses of RAS-related gene variants in psychiatric 
disorders in the elderly to also include the SNP rs5186 in the angiotensin II type 1 receptor 
(AGTR1) gene and the phenotype late life depression. The main aim of the study was to 
examine the influence of the AGTR1 SNP, as well as the ACE I/D polymorphism, on dementia 
and late-life depression in a population-based sample followed over twelve years. 
 
Material and Methods 
Participants 
Participants originate from two epidemiological studies in Gothenburg, Sweden, the 
Prospective Population Study of Women (PPSW) and the Gerontological and Geriatric 
Population Studies (H70), both which have been described in detail previously (Steen and 
Djurfeldt 1993; Bengtsson et al. 1997; Skoog 2004; Karlsson et al. 2009). The participants 
were sampled from the Swedish Population Register on the basis of their birth date and were 
born in 1908, 1914, 1918, 1922 and 1930. Both persons living in private households and in 
residential care were included. In total, there were 1495 eligible individuals in 2000-2001, and 
1051 agreed to participate (response rate 70.3%). Among these, 900 (86%) consented to 
donate their blood for genetic analyses. Due to the nature of the studies, the women (n=679) 
were aged 70-92 years and the men (n=221) aged 70 years. Follow-up psychiatric 
examinations were conducted in 2005-2006 and 2009-2010. There were 686 participants 
followed-up in 2005-06 (response rate among survivors 87 %), and 504 in 2009-10 (response 
rate among survivors 78 %).  Characteristics of the study sample are presented in Table 1.   
The study was approved by the Ethics Committee for Medical Research at the University of 
Gothenburg, and informed consent was obtained from all participants and/ or their relatives in 
cases of dementia. 
 
Neuropsychiatric examinations and interviews 
The clinical examinations were conducted at an outpatient department or in the participant’s 
home and included comprehensive social, functional, physical, neuropsychiatric and 
neuropsychological examinations, as well as close informant interviews.  
Semi-structured neuropsychiatric examinations were performed by trained psychiatric 
research nurses. These examinations included ratings of the past month’s psychiatric 
symptoms and signs according to the Comprehensive Psychopathological Rating Scale 
(CPRS),(Asberg et al. 1978), which is valid and reliable in older populations (van der Laan et 
al. 2005), Mini-International Neuropsychiatric Interview (Sheehan et al. 1998), self-reported 
history of depression, and assessment of current medications. Ratings of common symptoms 
and signs of dementia were performed (e.g. assessments of memory, orientation, general 
knowledge, apraxia, visuospatial function, understanding proverbs, following commands, 
naming ability and language) and has been described in detail previously (Skoog et al. 1993; 
Guo et al. 2007). Cognitive function was also measured with the Mini Mental State 
Examination (MMSE) (Folstein et al. 1975).  
 
The psychiatric nurses who performed the examinations were supervised and trained by 
psychiatrists. Inter-rater reliability between psychiatrists and nurses was studied in 50 
individuals who had dual ratings by either psychiatric research nurses or psychiatrists. Kappa 
values for the presence versus absence of symptoms and signs necessary to diagnose 
depression were between 0.62 and 1.00 indicating “good” (reference range kappa=0.61-0.80) 
or “excellent” (kappa=0.81-1.00) agreement. Inter-rater agreement for the symptoms and 
signs used to diagnose dementia was between good and excellent (kappa values between 0.74 
and 1.00) (Wancata et al. 2007). Close informant interviews were performed in 2000, 2005, 
and 2009. The interviews were semi-structured and comprised questions about changes in 
behaviour and intellectual function, psychiatric symptoms, activities of daily living, and, in 
cases of dementia, age of onset and disease course.  
 
Diagnoses  
Dementia was diagnosed by geriatric psychiatrists according to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-III-R) (APA 1987), based on symptoms rated during the 
neuropsychiatric examinations and information from the close informant interviews, as 
described previously (Skoog et al. 1993; Guo et al. 2007; Skoog et al. 2015). Incident cases of 
dementia up to year 2012 were also based on information from the Swedish Hospital 
Discharge Register (ICD-10: F00.1, F01.8, F01.9, F03.9, G30.9).  
 
Major and minor depression were diagnosed according to DSM-IV research criteria (Skoog et 
al. 1993; APA 1994)_ENREF_44, except that the use of the bereavement criterion was not 
applied, which makes the criteria the same as DSM-V (Maj 2012). Depression symptom 
burden was measured with the Montgomery-Åsberg Depression Scale (MADRS)(Asberg et 
al. 1978).    
  
Genotyping 
DNA was extracted from blood samples according to standard procedures. Genotyping of 
ACE rs1799752 and AGTR1 rs5186 was conducted according to Olsson et al (2004). Both 
polymorphisms were found to be in Hardy Weinberg equilibrium. APOE (gene map locus 
19q13.2) genotyping was performed by mini-sequencing as previously described in detail 
(Blennow et al. 2000). Genotypes were obtained for the two SNPs (rs7412 and rs429358), 
which are used to unambiguously define ε2, ε3, and ε4 alleles.  
 
Statistics 
Differences in distributions and mean values of sample characteristics (Table 1) were 
anlaysed using Fisher’s exact test or t-test. Associations between genotypes and dementia at 
baseline or depression were investigated by logistic regression models, while associations 
between genotypes and dementia during follow-up were investigated by Cox regression 
models. Three different models were tested; a crude model including only genotype data and 
data about diagnosis (model 1), a second model also including age and sex (when analyzing 
the total sample) as covariates (model 2), and a final model including APOE ɛ4 status as an 
additional covariate (model 3). When investigating depression, all analyses were performed 
both with and without exclusion of dementia up to year 2012. Associations with mean age at 
onset, as well as analyses of mean blood pressures at baseline versus ACE and AGTR1 
genotypes, were done using linear regression. The analyses were performed in SPSS 22, R 2.2 
or STATA v.13. 
 
Results 
Like previously reported for the II-genotype of ACE rs1799752 (Gustafson et al. 2010), the 
CC-genotype of AGTR1 rs5186 were associated with dementia at baseline (Table 2).  There 
were no interactions with sex. There was no relation between the polymorphisms and the 
development of dementia during follow-up (Table 3). In order to explore possible reasons for 
the diminished effect of the angiotensin-related polymorphisms during follow-up, we 
investigated the relation with age at onset of dementia. A significant association with onset 
age was seen only for rs1799752 in ACE (p=0.018). Individuals carrying the II-genotype have 
approximately 2 year earlier onset than individuals with the other two genotypes (mean age at 
onset 79.5 years for II and 81.7 years for ID+DD). There were no interactions with sex in any 
of these analyses.  
 
Regarding depression, we included all individuals who had major depression on at least one 
occasion during the study period, as this is a periodic disorder, not a chronic disorder as 
dementia. When the total number of individuals who developed depression up to year 2009 
was analyzed, significant associations with the II-genotype of ACE rs1799752, and a trend for 
an association with the CC-genotype of rs5186 in AGTR1 were found (Table 4). The 
significant associations with rs1799752 remained after exclusion of all individuals with 
dementia up to 2012. There were no interactions with sex.  
 
Since the investigated polymorphisms previously have been associated with hypertension, 
although with inconsistent results, we investigated the relation with mean systolic and 
diastolic blood pressure in the present sample at baseline. However, no associations could be 
found with either ACE rs1799752 or AGTR1 rs5186. 
 
Discussion 
In a previous study in this population, our research group reported an association between the 
ACE rs1799752 and dementia (Gustafson et al. 2010). In the present study, we report a similar 
association between another angiotensin-related SNP, rs5186 in AGTR1, and dementia at 
baseline. These two polymorphisms were not associated with dementia during follow-up. One 
possible explanation is the relation with age at onset of dementia, although this finding was 
significant only for rs1799752 in ACE. Interestingly, this result is in line with previous 
investigations of ACE in AD, showing an association between the rs1799752 proxy SNP 
rs4343 and age at onset(Kehoe et al. 2004). These findings emphasize the importance of 
considering age at onset and age of samples when evaluating the effect of different genetic 
variations. 
 
A significant association was found between carriers of the II-genotype rs1799752 in ACE 
and the cumulative prevalence and incidence of major depression during year 2000-2009. A 
trend in the same direction was seen for the CC-genotype of the AGTR1-SNP. This illustrates 
the importance of several follow-up examinations in genetic studies of depression, in order to 
detect more individuals with depression and to make the control group cleaner. Due to the 
high life-time prevalence of depression (Andrews et al. 2005; Moffitt et al. 2010), a large 
portion of persons in the control group will be misclassified in cross-sectional studies. The 
fact that we only had 9 years follow-up indicates that we probably missed some cases with 
life-time history of depression. The associations with depression remained also after exclusion 
of dementia up to year 2012, indicating that the result was not merely due to prodromal 
symptoms of dementia.  
 
There is a possibility that SNPs in angiotensin-related genes, such as ACE and AGTR1 interact 
in their effect on dementia and depression, since this type of epistasis have been shown in 
other disorders (Ye et al. 2003). Still no synergism between the high-risk genotypes could be 
observed in this study, probably because we were underpowered to detect such effects (only 
17 individuals carry both high-risk genotypes).    
 
The result of the present study suggests common mechanisms for dementia and late life 
depression. This is further supported by studies from our research group, reporting that white 
matter lesions and temporal lobe atrophy in 70-year-olds increased risk of both dementia and 
depression during 10-year follow-up (Gudmundsson et al. 2015), and that the APOEɛ4-allele 
was a risk factor for both disorders (Skoog et al. 2015). To our knowledge, this is the first 
study analyzing genotype-data of ACE rs1799752 and AGTR1 rs5186 versus both dementia 
and late life depression in a population based Caucasian sample. The ACE gene has been 
studied in the British MRC CFAS study, analysing both prevalent and incident dementia, 
reporting no associations (Yip et al. 2002; Keage et al. 2010). However, mean age at baseline 
was higher compared to the present study, and no analyses of possible associations with age at 
onset were performed. The only study specifically investigating AGTR1 in dementia was 
performed in a clinical population from Korea (Kim et al. 2006). In that study also ACE was 
included, but no associations were reported. In addition, the Asian study only examined the 
subtype VaD, while our results are based on a population-based study including all types of 
dementia. Also, as a result of different ethnicity, there is a deviation in allele frequencies, for 
example no individual in the Asian sample had the CC-genotype of rs5186. Interestingly, the 
result from the only previous population-based study of angiotensin-related genes in late life 
depression is in line with our study, and shows an association with a proxy-SNP of rs1799752 
in the ACE gene (Ancelin et al. 2013). 
 
Conflicting opinions about the role of ACE in the brain exist. The vascular hypothesis 
suggests that high ACE activity may increase the risk of dementia by increasing vascular risk, 
while the amyloid hypothesis implies that high ACE activity may decrease the risk of 
dementia by reducing the accumulation of amyloid  in the brain (Jochemsen et al. 2012). The 
latter is supported by the fact that the II-genotype of the ACE rs1799752, related to lowest 
enzymatic levels (Rigat et al. 1990), have been associated with an increased risk of AD 
(Webster et al. 2010; Lambert et al. 2013), in line with the results of our study. Furthermore, 
studies of white matter lesions and cortical brain atrophy in relation to ACE activity suggest 
both detrimental and beneficial effects of high ACE levels on the brain. Relation between the 
CC-genotype or the C-allele of AGTR1 rs5186 and hypertension (Niu and Qi 2010), as well as 
decreased white matter integrity in the brain (Taylor et al. 2013; Salminen et al. 2014), have 
been shown in several studies.  
 
The strengths with the present study are the representative population-based cohort, the 
comprehensive examinations performed by trained psychiatric nurses, as well as the long 
follow-up period and high response rate during follow-up. There are also some limitations. 
First, the small sample size makes some analyses hard to interpret, e.g. interactions between 
the investigated SNPs. Second, we were not able to classify subtypes of dementia. However, 
phenotypic overlap of VaD and AD is common, and these two forms of dementia may share 
common neuropathological mechanisms. White matter infarcts and cerebrovascular pathology 
are often present in individuals with AD, while senile plaques can be found in individuals 
with VaD (Leys et al. 1999). Furthermore, ischemic insults of the brain, such as in VaD, may 
stimulate formation of the pathological hallmarks of AD, i.e. neurofibrillary tangles and 
accumulation of amyloid precursor protein (Wen et al. 2004; Wen et al. 2004). Still, we 
cannot exclude the possibility that one of the investigated polymorphisms might be of 
importance mainly in AD and the other in VaD, perhaps by acting through different biological 
mechanisms. This is further indicated by previous studies showing an established relation 
with ACE I/D in AD, but not in VaD. Third, the high age of the sample prevent inferences to 
other age groups. Fourth, due to the merging of two different population studies (albeit 
examined with identical methods during the same time), the study is unbalanced regarding 
gender (Skoog et al. 2015). Therefore, the group older than 70 years at baseline only 
comprised women. Thus, our exploratory analyses regarding interactions with sex have to be 
interpreted cautiously. Fifth, although we had a nine-year follow-up, some of the participants 
may have had depressive episodes prior to baseline and others may have had such episodes 
between examination waves. Thus, we might still have underestimated the number with 
genetic risk for depression.  
 
Conclusively, in the investigated population-based sample of older individuals, genetic 
variation in angiotensin-related genes, especially in ACE, is associated with both dementia 
and major depression. Still, the results have to be interpreted with caution because of the 
small sample size, and further studies of these genes in population-based samples are 
warranted.  
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 Table 1. Characteristics of the study sample. 
 Total sample, n=900 
mean (sd) or n (%) 
Age at baseline year 2000 74.2 (5.5) 
Dementia year 2000 58 (6.4) 
Dementia up to year 2012 196 (21.8) 
Age at onset of dem 2000 76.2 (6.9) 
Age at onset of dem 2012 81.1 (7.0) 
Major dep up to year 2009 80 (8.9) 
Minor dep up to year 2009 250 (27.8) 
Major dep without dementia1 64 (7.1) 
Minor dep without dementia1 183 (20.3) 
APOE 4 allele 254 (28.2) 
 1Depression after exclusion of dementia up to year 2012. 
 
Table 2.  Associations between the polymorphisms rs5186 in the gene AGTR1 at baseline 
year 2000. 
Gene, SNP and 
genotype 
dementia   
  
No dementia 
  
crude 
OR (95% CI) 
crude 
p-value 
adjusted* 
OR (95% CI) 
adjusted* 
p-value 
adjusted**
OR (95% C
AGTR1_rs5186 
 
 
 
      
total sample n (%) n (%)      
AA 26 (44.8) 459 (54.5) --- --- --- --- ---
AC 20 (34.5) 323 (38.4) 0.99 (0.52-1.82) 0.96 1.00 (0.52-1.86) 0.99 0.99 (0.52
CC 12 (20.7) 60 (7.1) 3.45 (1.56-7.2) 0.001 3.25 (1.42-7.06) 0.004 3.19 (1.39
*Model including age and sex as covariates. 
**Model including age, sex and APOE 4 status as covariates. 
 
Table 3. Associations between polymorphisms in the genes AGTR1 and ACE and dementia 
during follow up. 
Gene, SNP and 
genotype 
dementia   
 
no dementia 
 
crude 
HR (95% CI) 
crude 
p-value 
adjusted* 
HR (95% CI) 
adjusted* 
p-value 
adjusted** 
HR (95% CI)
AGTR1_rs5186        
total sample n (%) n (%)      
AA 68 (49.3) 391 (55.5) --- --- --- --- --- 
AC 61 (44.2) 262 (37.2) 1.31 (0.93-1.86) 0.12 1.25 (0.88-1.77) 0.20 1.26 (0.89-1.7
CC 9 (6.5) 51 (7.2) 0.99 (0.49-1.98) 0.98 0.90 (0.45-1.81) 0.78 0.88 (0.44-1.7
        
ACE_rs1799752        
total sample        
DD 40 (29.2) 206 (29.3) --- --- --- --- --- 
ID 66 (48.2) 326 (46.4) 1.02 (0.69-1.52) 0.90 1.02 (0.69-1.51) 0.93 0.99 (0.66-1.4
II 31 (22.6) 171 (24.3) 0.95 (0.59-1.51 0.82 0.92 (0.58-1.47) 0.73 0.94 (0.59-1.5
*Model including age at baseline and sex as covariates. 
**Model including age at baseline, sex and APOE 4 status as covariates. 
Table 4. Associations between polymorphisms in the genes AGTR1 and ACE and ever major 
depression up to year 2009. 
Gene, SNP and 
genotype 
ever maj dep  
 
no dep 
 
crude 
OR (95% CI) 
crude 
p-value 
adjusted* 
OR (95% CI) 
adjusted* 
p-value 
adjusted
OR (95%
AGTR1_rs5186 n (%) n (%)      
total sample        
AA 40 (50.0) 445 (54.3) --- --- --- --- --
AC 28 (35.0) 315 (38.4) 0.96 (0.57-1.59) 0.87 0.98 (0.58-1.62) 0.93 0.97 (0.5
CC 12 (15.0) 60 (7.3) 1.94 (0.88-3.96) 0.08 1.83 (0.82-3.74) 0.12 1.79 (0.8
       
ACE_rs1799752       
total sample       
DD 17 (21.3) 247 (30.2) --- --- --- --- --
ID 37 (46.3) 372 (45.5) 1.49 (0.83-2.82) 0.20 1.53 (0.85-2.90) 0.17 1.53 (0.8
II 26 (32.5) 199 (24.3) 2.00 (1.05-3.91) 0.04 2.14 (1.13-4.20) 0.02 2.17 (1.1
*Model including age at baseline and sex as covariates. 
**Model including age at baseline, sex and APOE 4 status as covariates. 
 
